Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
3.730
-0.060 (-1.58%)
Dec 5, 2025, 4:00 PM EST - Market closed
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Esperion Therapeutics stock have an average target of 6.86, with a low estimate of 3.00 and a high estimate of 16. The average target predicts an increase of 83.91% from the current stock price of 3.73.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $9 | Buy | Initiates | $9 | +141.29% | Nov 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +328.95% | Sep 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +328.95% | Jun 17, 2025 |
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +7.24% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +328.95% | Apr 25, 2025 |
Financial Forecast
Revenue This Year
416.89M
from 332.31M
Increased by 25.45%
Revenue Next Year
399.07M
from 416.89M
Decreased by -4.27%
EPS This Year
-0.08
from -0.28
EPS Next Year
0.04
from -0.08
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 468.4M | 514.5M | ||||
| Avg | 416.9M | 399.1M | ||||
| Low | 341.0M | 332.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 41.0% | 23.4% | ||||
| Avg | 25.5% | -4.3% | ||||
| Low | 2.6% | -20.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.24 | 0.42 | ||||
| Avg | -0.08 | 0.04 | ||||
| Low | -0.41 | -0.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.